SYMMETRIC VACCINE EFFICACY

A PREPRINT

Lucy D'Agostino McGowan^{1*}, Sarah C. Lotspeich¹, and Michael G. Hudgens²

¹Department of Statistical Sciences, Wake Forest University, Winston-Salem, NC 27106 ²Department of Biostatistics University of North Carolina at Chapel Hill, Chapel Hill, NC 27599

December 9, 2025

ABSTRACT

Traditional measures of vaccine efficacy (VE) are inherently asymmetric, constrained above by 1 but unbounded below. As a result, VE estimates and corresponding confidence intervals can extend far below zero, making interpretation difficult and potentially obscuring whether the apparent effect reflects true harm or simply statistical uncertainty. The proposed symmetric vaccine efficacy (SVE) is a bounded and interpretable alternative to VE that maintains desirable statistical properties while resolving these asymmetries. SVE is defined as a symmetric transformation of infection risks, with possible values within [-1,1], providing a common scale for both beneficial and harmful vaccine effects. This paper describes the relationship between SVE and traditional VE, considers inference about SVE, and illustrates the utility of the proposed measure by reanalyzing data from a randomized trial of a candidate HIV vaccine. Open-source tools for computing estimates of SVE and corresponding confidence intervals are available in R through the sve package.

Keywords Communication; Infectious disease; Public health; Relative risk; Symmetric metrics; Vaccination.

1 Introduction

Vaccines are one of the most effective public health interventions for preventing infectious diseases. Quantifying vaccine effects accurately and providing interpretable estimates is critical for regulatory decisions, public health policy, and individual risk communication. The most commonly used measure of vaccine performance is *vaccine efficacy* (VE), typically defined as one minus the relative risk of infection if vaccinated versus not vaccinated (Halloran et al., 1991; World Health Organization, 2025). Throughout this paper, the term *infection* is used to describe the outcome of interest for consistency and clarity; however, the framework applies equally to any binary outcome commonly measured in vaccine trials (e.g., symptomatic disease, hospitalization, or death).

The parameter space for traditional VE is inherently asymmetric, with VE bounded above by 1 (complete protection afforded by vaccination) but unbounded below. Consequently, VE estimates and corresponding confidence intervals can take on extreme negative values when the vaccine group experiences higher infection rates or the numbers of individuals infected in both groups are small. Such extremes have been observed in certain subgroups of HIV vaccine trials (rgp120 HIV Vaccine Study Group, 2005) and analyses of COVID-19 vaccine trials (Buchan et al., 2022; Bodner et al., 2023; Hansen et al., 2021). Asymmetry in VE complicates interpretation, particularly when communicating results in settings with small numbers of infections where confidence intervals can be wide.

Symmetrization of effect measures has been proposed in other contexts to improve interpretability by placing beneficial and harmful treatment effects on a common scale. For example, Berry and Ayers (2006) introduced the *symmetrized* percent change (SPC) for treatment comparisons from baseline, demonstrating improved interpretability without loss of statistical efficiency. This paper considers a similar approach to vaccine evaluation, defining a *symmetric vaccine* efficacy (SVE) metric that provides a bounded, interpretable measure of vaccine effect ranging from -1 (maximal harm) to 1 (maximal protection).

The outline of the remainder of this paper is as follows. Section 2 compares the proposed SVE estimand to the traditional VE parameter. Section 3 considers inference about the SVE estimand. Section 4 examines operating characteristics of the inferential methods through simulation. Section 5 illustrates the approach using data from a large HIV vaccine trial (rgp120 HIV Vaccine Study Group, 2005), demonstrating the interpretational advantages of SVE over traditional VE. Section 6 describes R code for estimating SVE and corresponding confidence intervals.

2 Symmetric Vaccine Efficacy

VE is the standard measure used to quantify the effect of a vaccine (World Health Organization, 2025). In practice, VE is often defined as one minus a relative measure of risk, such as the relative risk or hazard ratio. For example, in a trial setting with infection probabilities p_1 if vaccinated and p_0 if not vaccinated, the VE parameter is often defined as

$$VE = 1 - \frac{p_1}{p_0},\tag{1}$$

with VE = 1 corresponding to complete protection (i.e., no risk of infection if vaccinated) and VE = 0 corresponding to the null of no effect (i.e., equal risk regardless of whether vaccinated) (Halloran et al., 1991). The VE parameter as defined in (1) is bounded above by 1 but unbounded below, making it inherently asymmetric.

Alternatively, a symmetric measure of vaccine efficacy (SVE) can be defined as

$$SVE = \frac{p_0 - p_1}{\max(p_0, p_1)}.$$
 (2)

By construction, SVE is bounded between -1 and 1, and has a straightforward interpretation as follows.

- (i) When $p_0 > p_1$, SVE = $1 p_1/p_0$ will be greater than 0 and equal to VE. Thus, in this case, SVE has the same interpretation as the traditional VE metric, i.e., the proportional reduction in risk due to vaccination. SVE values closer to 1 indicate a stronger protective effect.
- (ii) When $p_1 > p_0$, SVE = $p_0/p_1 1$ will be less than zero. Negative SVE captures the proportional increase in risk due to vaccination, with values closer to -1 corresponding to more possible harm on the same scale as the protective effect.

To illustrate the contrast between traditional VE and the proposed SVE, Figure 1 shows L'Abbe plots (L'Abbé et al., 1987) of infection probabilities if vaccinated versus if not vaccinated. In these plots, iso-effect lines correspond to pairs of infection probabilities (p_0, p_1) with the same effect size. For example, the 45-degree line indicates pairs of equal infection probabilities (i.e., the vaccine has no effect such that infection risk is the same in both groups). Iso-effect lines for traditional VE shown in Figure 1a correspond to $p_1 = (1 - \text{VE})p_0$, whereas the iso-effect lines for SVE shown in Figure 1b are given by $p_1 = (1 - \text{SVE})p_0$ if $\text{SVE} \geq 0$ and $p_1 = p_0/(1 + \text{SVE})$ if SVE < 0. In contrast to VE, the SVE iso-effect lines are symmetric about the 45-degree line, with SVE bounded between -1 and 1 for all possible values of (p_0, p_1) . That is, SVE is a balanced metric where both protection and harm are represented on the same bounded scale, highlighting its interpretability advantages.

3 Inference for Symmetric Vaccine Efficacy

Consider a randomized trial with perfect compliance and no loss to follow-up. Let $X_0 \sim \text{Binomial}(n_0, p_0)$ and $X_1 \sim \text{Binomial}(n_1, p_1)$ denote the numbers of infections observed in the unvaccinated and vaccinated groups, respectively, where n_0 and n_1 are the group sample sizes (Halloran et al., 1991). Assume $p_0, p_1 \in (0, 1)$. Denote the empirical risks in the two groups by $\hat{p}_0 = X_0/n_0$ and $\hat{p}_1 = X_1/n_1$, which are unbiased estimators of the true infection risks p_0 and p_1 . Define the plug-in estimator of SVE to be $\widehat{\text{SVE}} = (\hat{p}_0 - \hat{p}_1)/\max(\hat{p}_0, \hat{p}_1)$, which is obtained by substituting the empirical risks for the true risks in (2). By the law of large numbers and continuous mapping theorem, it follows that $\widehat{\text{SVE}}$ is a consistent estimator of SVE as $n_0, n_1 \to \infty$. Like other ratio estimators (Jewell, 1986), $\widehat{\text{SVE}}$ will in general exhibit finite-sample bias. In Web Appendix B.1 a bias-corrected estimator is proposed which may be preferred in small sample size settings. In Sections 3.1 and 3.2, confidence intervals (CIs) for SVE using the profile likelihood and delta method are presented.




Figure 1: L'Abbe plots illustrating iso-effect lines for (a) traditional VE and (b) SVE. Each line represents a fixed effect size, with 20 evenly spaced values from -0.95 to 0.95 ranging from strong harm to strong protection represented by the line color. The dashed diagonal line at y=x indicates equal risk in vaccinated and unvaccinated groups. For traditional VE, the iso-effect lines above this diagonal (negative effect sizes) appear compressed compared to those below it (positive effect sizes), illustrating the metric's inherent asymmetry. By contrast, the symmetric SVE iso-effect lines remain bounded and mirror protective and harmful effects around the diagonal, providing a more interpretable measure of vaccine efficacy.

3.1 Profile Likelihood Confidence Intervals

A confidence interval for SVE can be obtained by inverting a likelihood ratio test, as follows. First note that \hat{p}_0 and \hat{p}_1 are the unconstrained maximum likelihood estimators (MLEs) of the log-likelihood

$$\ell(p_0, p_1) = \sum_{j=0}^{1} \{ X_j \log(p_j) + (n_j - X_j) \log(1 - p_j) \}.$$
(3)

Likelihood-based inference of the SVE parameter can be achieved via the profile likelihood, wherein for any value of SVE the likelihood is maximized over p_0 and p_1 , subject to the functional constraints implied by the value of SVE. In particular, if SVE ≥ 0 , then the constraint is $p_1 = p_0(1 - \text{SVE})$. On the other hand, if SVE < 0, then the constraint is $p_0 = p_1(1 + \text{SVE})$. Therefore the profile log-likelihood for SVE is

$$\ell_p(SVE) = \begin{cases} \sup_{p_0 \in (0,1)} \ell(p_0, p_0(1 - SVE)) & \text{if SVE} \in [0,1), \\ \sup_{p_1 \in (0,1)} \ell(p_1(1 + SVE), p_1) & \text{if SVE} \in (-1,0). \end{cases}$$
(4)

The two cases in (4) each entail a one-dimensional maximization over either p_0 or p_1 which can be easily solved using standard one-dimensional numerical optimization algorithms.

Consider testing the null hypothesis H_0 : SVE = s for some $s \in (-1,1)$. Define the likelihood ratio statistic $\Lambda(s) = 2\{\ell(\hat{p}_0,\hat{p}_1) - \ell_p(s)\}$, where $\ell(\hat{p}_0,\hat{p}_1)$ is the maximum of the unconstrained log-likelihood (3), and $\ell_p(s)$ is the profile log-likelihood (4) evaluated at SVE = s. Larger values of $\Lambda(s)$ provide stronger evidence against H_0 : SVE = s.

Under standard regularity conditions as $n_0, n_1 \to \infty$, $\Lambda(s)$ converges in distribution to a χ^2_1 under the null. Using this asymptotic approximation, the likelihood ratio test can be inverted in the usual fashion to construct a CI for SVE. Specifically, the $(1-\alpha)\%$ profile likelihood CI for SVE is $\{s \in (-1,1): \Lambda(s) \le \chi^2_{1,1-\alpha}\}$, where $\chi^2_{1,1-\alpha}$ denotes a $(1-\alpha)$ -quantile of a χ^2_1 distribution.

3.2 Wald Confidence Intervals

For large samples, Wald confidence intervals provide a computationally efficient alternative to the profile likelihood approach. Let $n = n_0 + n_1$ be the total trial size and assume $n_0/n \to \lambda \in (0,1)$ as $n \to \infty$. Then, under standard

regularity conditions and assuming independence between groups, by the bivariate central limit theorem

$$\sqrt{n} \begin{pmatrix} \hat{p}_0 - p_0 \\ \hat{p}_1 - p_1 \end{pmatrix} \xrightarrow{d} \mathcal{N} (\mathbf{0}, \mathbf{\Sigma}), \text{ where } \mathbf{\Sigma} = \begin{pmatrix} p_0(1 - p_0)/\lambda & 0 \\ 0 & p_1(1 - p_1)/(1 - \lambda) \end{pmatrix}.$$

The multivariate delta method in turn implies that \widehat{SVE} is also asymptotically normal. In particular, let $g(p_0,p_1)=SVE=(p_0-p_1)/\max(p_0,p_1)$ such that $g(\hat{p}_0,\hat{p}_1)=\widehat{SVE}$. Note that the gradient ∇g exists and is continuous throughout the interior of the parameter space, despite the maximum operator in the denominator (see Web Appendix A). Therefore, $\sqrt{n}(\widehat{SVE}-SVE) \stackrel{d}{\to} \mathcal{N}(0,\nabla g^{\top}\Sigma\nabla g)$. The asymptotic variance can be consistently estimated by replacing p_0 and p_1 with \hat{p}_0 and \hat{p}_1 , and p_1 with p_0 with p_0 and p_1 with p_0 with p_0

$$\widehat{\text{Var}}(\widehat{\text{SVE}}) = \frac{\hat{p}_1^2 \hat{\sigma}_0^2 + \hat{p}_0^2 \hat{\sigma}_1^2}{\{\max(\hat{p}_0, \hat{p}_1)\}^4},\tag{5}$$

which simplifies to $(\hat{\sigma}_0^2 + \hat{\sigma}_1^2)/\hat{p}^2$ when $\hat{p}_0 = \hat{p}_1 = \hat{p}$. Thus a $100(1-\alpha)\%$ Wald-type CI for SVE is $\widehat{\text{SVE}} \pm z_{1-\alpha/2}\widehat{\text{Var}}(\widehat{\text{SVE}})^{1/2}$, where $z_{1-\alpha/2}$ is the $(1-\alpha/2)$ quantile of the standard normal distribution. These CIs are asymptotically valid but can include values outside the parameter space [-1,1] when the SVE estimate lies near the boundaries or in settings where there is considerable uncertainty (e.g., in small samples).

Wald CIs may also be computed on a transformed scale to ensure that the lower and upper endpoints of the CI remain within the parameter space [-1,1] after back-transformation. For example, the SVE estimator can be transformed using the inverse hyperbolic tangent $\hat{u} = \tanh^{-1}(\widehat{SVE}) = 0.5 \log\{(1 + \widehat{SVE})/(1 - \widehat{SVE})\}$, where \hat{u} can take on any real value in $(-\infty,\infty)$ (Fisher, 1921; Hotelling, 1953; van der Vaart, 1998). By the delta method, $Var(\hat{u}) \approx Var(\widehat{SVE})/(1 - SVE^2)^2$ for which an estimator $\widehat{Var}(\hat{u})$ can be constructed by replacing SVE with \widehat{SVE} and $Var(\widehat{SVE})$ with the variance estimator in (5). The corresponding CI for SVE is obtained by back-transformation:

$$\left[\tanh\left(\widehat{u}-z_{1-\alpha/2}\sqrt{\widehat{\mathrm{Var}}(\widehat{u})}\right),\tanh\left(\widehat{u}+z_{1-\alpha/2}\sqrt{\widehat{\mathrm{Var}}(\widehat{u})}\right)\right].$$

Hereafter, these are termed tanh-Wald intervals.

3.3 Extension to Relative Effect Measures

In some settings a vaccine's effect may be estimated by $\widehat{\text{VE}} = 1 - \hat{\theta}$ where $\hat{\theta}$ is an estimated rate ratio from a Poisson regression model or an estimated hazard ratio from a Cox proportional hazards model. The SVE framework extends naturally to any multiplicative relative effect measure θ by defining

$$SVE = \frac{1 - \theta}{\max(1, \theta)},\tag{6}$$

where $\theta=1$ corresponds to the vaccine having no effect, in which case SVE = 0. When $\theta<1$, the vaccine is protective and (6) simplifies to SVE = $1-\theta$. When $\theta>1$, the vaccine is harmful and (6) becomes SVE = $(1-\theta)/\theta$. In this setting SVE can be estimating by replacing θ in (6) with an estimator $\hat{\theta}$ obtained using standard likelihood-based procedures, for example by the MLE from a Poisson model or the maximum partial likelihood estimator from a Cox proportional hazards models. Let $\ell(\theta)$ denote the corresponding log-likelihood or partial log-likelihood, and let $\hat{\theta}$ be the unconstrained maximizer of $\ell(\theta)$.

Confidence intervals for SVE defined by (6) can be constructed using profile likelihood or the delta method, similar to Sections 3.1 and 3.2. To construct profile likelihood CIs, for each candidate SVE value s, the profile likelihood $\ell_p(s)$ is obtained by maximizing $\ell(\theta)$ subject to SVE = s. The resulting likelihood ratio statistic $\Lambda(s) = 2\{\ell(\hat{\theta}) - \ell_p(s)\}$ quantifies evidence against H_0 : SVE = s. Under standard regularity conditions as $n_0, n_1 \to \infty$, $\Lambda(s)$ is asymptotically χ_1^2 under the null. The corresponding $(1-\alpha)$ profile likelihood confidence interval again has the form $\{s \in (-1,1): \Lambda(s) \le \chi_{1,1-\alpha}^2\}$.

Wald-type CIs may be obtained using the delta method applied to the log-scale relative effect. Let $\hat{\phi} = \log(\hat{\theta})$ with estimated variance $\widehat{\text{Var}}(\hat{\phi})$. The variance of $\widehat{\text{SVE}}$ can then be estimated by

$$\widehat{\text{Var}}(\widehat{\text{SVE}}) = \frac{\widehat{\text{Var}}(\hat{\phi})}{\{\max(\hat{\theta}, \hat{\theta}^{-1})\}^2}.$$
(7)

When $\hat{\theta} = 1$, (7) reduces to $\widehat{\text{Var}}(\hat{\phi})$.

4 Operating Characteristics

This section presents results from Monte Carlo simulation studies of the SVE estimator and corresponding CIs described in Section 3. Bias, sampling variability, and CI coverage were examined across a range of infection probabilities and group sample sizes. Comparisons were also made to traditional VE-based inference in terms of CI width and type I error rate.

4.1 Simulation Setup

In each simulated data set (replicate), the numbers of infected individuals in the vaccinated and unvaccinated groups were generated independently from binomial distributions with sample sizes n_1 and n_0 and infection probabilities p_1 and p_0 , respectively. Underlying parameters were varied over a grid of values. Infection probabilities were set to $p_0, p_1 \in \{0.1, 0.2, \dots, 0.9\}$ and sample sizes $n_0, n_1 \in \{100, 250, 1000\}$ were used.

For each setting, 10,000 replicates were generated. For each replicate, the empirical infection risks \hat{p}_1 and \hat{p}_0 were used to compute \widehat{SVE} along with profile likelihood, original-scale Wald, and tanh-Wald 95% CIs. Coverage probabilities were estimated by the proportions of CIs that contained the true SVE value. Type I error rates were estimated by the proportions of intervals that did not contain 0 when the true SVE value was 0, i.e., when $p_0 = p_1$.

4.2 Simulation Results

Bias of SVE was negligible and the average variance estimates (5) closely approximated the empirical variance across the range of infection probabilities and sample sizes considered (see Web Figures 1 and 2). Figure 2 displays the empirical coverage probabilities for the profile likelihood, original-scale Wald, and tanh-Wald CIs as a function of true SVE, stratified by sample size. Across all scenarios, the profile likelihood intervals provided coverage probabilities closest to the nominal 95% level. For small sample sizes ($n_0 = n_1 = 100$), the profile likelihood and tanh-Wald intervals maintained coverage closer to the nominal 95% level across the full range of SVE values, while the original-scale Wald intervals tended to undercover near extremes (i.e., when the true SVE is close to -1 or 1). As sample sizes increased, coverage for all three CIs stabilized around 95%.

The empirical type I error rates for the setting when SVE = 0 (the null case) are presented in Web Appendix B.4 (Web Figure 4). The type I error was well controlled when sample sizes were large and balanced, whereas smaller or imbalanced designs led to inflated type I errors for the Wald intervals. The empirical type I error was closest to the nominal 5% for the profile likelihood intervals, followed by the tanh-Wald intervals, and poorest for the original-scale Wald intervals.

4.3 Comparison to Traditional Vaccine Efficacy

Figure 3 compares SVE 95% CIs (tanh-Wald) to traditional VE 95% CIs for 25 randomly selected simulated data sets when $p_0 = p_1 = 0.1$ and $n_0 = n_1 = 100$. The SVE intervals are symmetrically distributed around the null of 0. However, traditional VE estimates yield highly asymmetric intervals, with the lower bound often extending far below zero and potentially giving the false impression that an ineffective vaccine is actually harmful.

Additional comparison of the widths of 95% CIs for SVE and traditional VE for simulations where $n_0=n_1=1{,}000$ are presented in Web Appendix B.3 (Web Figure 3). When the vaccine was protective (i.e., $p_1 < p_0$), estimates of SVE and VE tended to be similar and not surprisingly the corresponding CIs had similar average width. However, when the vaccine was harmful (i.e., $p_1 > p_0$), CIs for traditional VE became extremely wide, while those for SVE remained stable. CIs for traditional VE were sometimes more than 80 times as wide as those for SVE in the extreme cases (i.e., when p_1 was much higher than p_0).

5 Application to an HIV Vaccine Trial

VAX004 was a placebo-controlled phase 3 trial of a recombinant glycoprotein 120 (rgp120) vaccine designed to prevent HIV-1 infection (rgp120 HIV Vaccine Study Group, 2005). The trial randomized 5,403 participants (2:1 allocation, $n_1 = 3,598$, $n_0 = 1,805$) to receive seven injections of the rgp120 vaccine or placebo over 30 months, with HIV-1 seroconversion as the primary endpoint. The analysis presented here utilizes the number of HIV-1 infections in the vaccine and placebo groups from Table 3 of rgp120 HIV Vaccine Study Group (2005), with VE estimated as one minus the ratio of the proportion infected in the two trial arms. Due to the unavailability of individual-level data, the hazard ratio from a Cox proportional hazards model, as reported in the original study, was not estimated.




Figure 2: Empirical coverage probabilities of 95% confidence intervals (CIs) of symmetric vaccine efficacy (SVE) as a function of true SVE values. Three types of CIs were considered: a profile likelihood interval (Profile), a Wald interval on the original SVE scale (Wald), and a back-transformed tanh-Wald interval (tanh-Wald). Each panel corresponds to a combination of sample sizes for the vaccinated and unvaccinated groups with columns corresponding to values of $n_1 \in \{100, 250, 1000\}$ and rows to $n_0 \in \{100, 250, 1000\}$. Coverage across the full range of SVE values is close to the nominal level for the profile likelihood and tanh-Wald intervals, with modest undercoverage for the original-scale Wald intervals at smaller sample sizes. Larger sample sizes stabilize coverage for all methods.

VE was estimated overall and across several subgroups (e.g., by age, race, and baseline behavioral risk score), as in the original study. Overall and subgroup-level infection proportions as well as VE and SVE estimates are given in Web Appendix C (Web Table 1). Figure 4 presents a forest plot of $\widehat{\text{VE}}$ and $\widehat{\text{SVE}}$ with 95% CIs across the subgroups. The 95% CIs for the SVE were calculated using the profile likelihood method.

The results in Figure 4 illustrate two key advantages of SVE over traditional VE. First, $\widehat{\text{SVE}}$ and the corresponding profile likelihood CI are bounded within [-1,1], which precludes extremely negative point estimates or CI endpoints. This is particularly important in smaller subgroups where there may be substantial uncertainty. For example, in the low baseline behavioral risk score subgroup, the VE 95% CI extends far below zero (-1.88 to 0.26), whereas the SVE 95% CI only spans -0.67 to 0.23.

Second, as a symmetric measure, SVE is easier to interpret than traditional VE. A negative SVE value indicates a protective effect of the placebo relative to the vaccine on the same scale for which a positive SVE indicates a protective effect of the vaccine relative to the placebo. For example, in the low baseline behavioral risk score subgroup, the lower bound -0.67 of the SVE CI indicates that the placebo group had 67% reduced infection risk relative to the vaccine group, while the CI upper bound 0.23 indicates that the vaccine group had 23% reduced infection risk relative to the placebo group. For this particular subgroup, there is considerable uncertainty due to the small sample sizes and relatively low proportion infected (2.9% in the vaccinated group versus 1.8% in the unvaccinated group). As a result, the CI for traditional VE occupies a disproportionately large span in the forest plot in Figure 4, which may give the misleading impression that the vaccine is likely to be harmful in this subgroup. To the contrary, these results plausibly mirror the simulated results in Figure 3, where the true effect is null rather than harmful. On the other hand, SVE provides a more balanced depiction of the possible vaccine effects across the subgroups. The bounded CIs have more reasonable width, better reflecting the underlying uncertainty without potentially implying exaggerated harm.




Figure 3: Forest plot of vaccine effect estimates and confidence intervals from 25 simulated data sets under the null (no vaccine effect) with infection risk $p_0 = p_1 = 0.1$ and sample sizes $n_0 = n_1 = 100$. Each point represents the estimated effect with error bars representing 95% CIs for symmetric vaccine efficacy (SVE) and traditional vaccine efficacy (VE). SVE intervals (calculated as tanh-Wald intervals) are guaranteed to be contained [-1,1] and symmetrically distributed around the null, whereas traditional VE intervals are highly asymmetric, with lower bounds extending far below zero.

6 Software Implementation in R

To facilitate estimation of SVE and it associated uncertainty, the R package sve was developed. The package provides functions for estimating SVE, the estimator's variance, and CIs as described in Section 3. The sve package can be installed from GitHub using the devtools package:

```
# install.packages("devtools")
devtools::install_github("LucyMcGowan/sve")
```

The core function est_sve() outputs an SVE estimate with a corresponding CI based on inputs consisting of the observed number of infections and sample sizes for the vaccinated and unvaccinated groups. For example, suppose in a two-arm placebo-controlled randomized vaccine trial that the observed proportion of infected participants is $\hat{p}_0 = 0.1$ in the placebo arm and $\hat{p}_1 = 0.05$ in the vaccine arm, with $n_0 = n_1 = 1000$ participants in each arm. This code

Here, the estimated SVE is 0.50, with 95% CI (0.31, 0.64) calculated using the profile likelihood method. The profile likelihood method is applied by default (method = "profile"); to use tanh-Wald intervals or original-scale Wald intervals instead, the user may select method = "tanh-wald" or method = "wald".

The sve_from_model() function computes estimates and CIs of SVE from estimates of a relative effect measure (e.g., hazard ratio from a Cox model, or rate ratio from Poisson regression) as described in Section 3.3. For example, a




Figure 4: Forest plot comparing traditional vaccine efficacy (VE) and symmetric vaccine efficacy (SVE) against HIV-1 infection in the rgp120 Trial. Each point represents the estimated efficacy with error bars representing 95% CIs. SVE CIs were calculated using the profile likelihood method. Data from rgp120 HIV Vaccine Study Group (2005).

Cox-model based estimate of SVE and corresponding profile likelihood 95% CI can be computed for the simulated trial dataset (sim_trial_data) included in the sve package via the following code:

7 Discussion

Traditional VE is widely used and easily interpretable when the vaccine is protective and uncertainty is small (e.g., in large trials). However, VE's inherent asymmetry can create difficulties in interpretability and communication. In particular, VE is unbounded below which can lead to highly asymmetric CIs in practice. Resulting extreme negative values of the VE can misleadingly suggest that a vaccine is harmful when the true effect may simply be small or null.

The symmetric vaccine efficacy (SVE) proposed in this paper addresses these limitations by defining efficacy on a bounded symmetric scale from -1 (maximally harmful) to 1 (maximally protective). This scale provides a natural and interpretable measure that treats protection and harm equivalently. Standard large sample frequentist inference is considered in the randomized trial setting where a binary outcome (e.g., infection) is observed for all trial participants. SVE can easily be adapted to accommodate other relative effect measures. For example, in vaccine trials where time to infection is the primary outcome, VE is commonly estimated as one minus the hazard ratio from a Cox proportional hazards model, which can be used in place of the relative risk in the SVE estimator, as described in Section 3.3. To support broad use of SVE, open-source software is provided for implementing the SVE estimator in R, as described in Section 6.

In Monte Carlo simulations, the SVE estimator and corresponding profile likelihood and tanh-Wald confidence intervals performed well across a wide range of settings. Under the null (when the vaccine has no effect), CIs for the SVE remain symmetric around the null, while those for traditional VE can be severely asymmetric. This feature of SVE may be particularly important for subgroup analyses and early-stage studies where small numbers of infections may lead to misleadingly wide or negative lower bounds for traditional VE.

The practical advantages of SVE are highlighted in the HIV vaccine trial analysis presented in Section 5. In one subgroup, the traditional VE 95% CI had a strongly negative lower bound, visually dominating forest plots and potentially giving the false impression that the vaccine was harmful. In contrast, SVE produced a bounded interval for all subgroups while accurately conveying the uncertainty in these estimates. This improved interpretability is especially valuable for communicating findings to non-technical audiences, policymakers, or the public, by whom negative VE estimates can be easily misinterpreted and potentially cause disproportionate concern. Relative effect measures are inherently challenging to interpret (Dupont and Plummer Jr, 1996; Brown, 2022), and the additional asymmetry of traditional VE can exacerbate misunderstandings.

Data Availability

Code to replicate all analyses, tables, and figures can be found on GitHub here: https://github.com/LucyMcGowan/symmetric-ve. The data referenced in Section 5 were obtained from Table 3 of rgp120 HIV Vaccine Study Group (2005) and have also been made available in our GitHub repository.

Acknowledgments

Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under Award Number R37 AI054165.

Supplementary Materials

Web Appendices, Tables, and Figures referenced in Sections 3-5 are available with this paper.

References

- Berry, D. A. and Ayers, G. D. (2006). Symmetrized percent change for treatment comparisons. *The American Statistician* **60**, 27–31.
- Bodner, K., Irvine, M. A., Kwong, J. C., and Mishra, S. (2023). Observed negative vaccine effectiveness could be the canary in the coal mine for biases in observational COVID-19 studies. *International Journal of Infectious Diseases* **131**, 111–114.
- Brown, R. B. (2022). Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy. *Dialogues in Health* **1,** 100074.
- Buchan, S. A., Chung, H., Brown, K. A., Austin, P. C., Fell, D. B., Gubbay, J. B., Nasreen, S., Schwartz, K. L., Sundaram, M. E., Tadrous, M., et al. (2022). Estimated effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. *JAMA Network Open* 5, e2232760–e2232760.
- Dupont, W. D. and Plummer Jr, W. D. (1996). Understanding the relationship between relative and absolute risk. *Cancer: Interdisciplinary International Journal of the American Cancer Society* **77**, 2193–2199.
- Fisher, R. A. (1921). On the "probable error" of a coefficient of correlation deduced from a small sample. *Metron* 1, 3–32.
- Halloran, M. E., Haber, M., Longini Jr, I. M., and Struchiner, C. J. (1991). Direct and indirect effects in vaccine efficacy and effectiveness. *American Journal of Epidemiology* **133**, 323–331.
- Hansen, C. H., Schelde, A. B., Moustsen-Helm, I. R., Emborg, H.-D., Krause, T. G., Mølbak, K., and Valentiner-Branth, P. (2021). Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. *MedRxiv* https://doi.org/10.1101/2021.12.20.21267966.

- Hotelling, H. (1953). New light on the correlation coefficient and its transforms. *Journal of the Royal Statistical Society. Series B (Methodological)* **15,** 193–232.
- Jewell, N. P. (1986). On the bias of commonly used measures of association for 2 x 2 tables. *Biometrics* 42, 351–358.
- L'Abbé, K. A., Detsky, A. S., and O'Rourke, K. (1987). Meta-analysis in clinical research. *Annals of Internal Medicine* **107,** 224–233.
- rgp120 HIV Vaccine Study Group (2005). Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. *The Journal of Infectious Diseases* **191**, 654–665.
- van der Vaart, A. W. (1998). Asymptotic Statistics, volume 3. Cambridge University Press.
- World Health Organization (2025). Design of vaccine efficacy trials to be used during public health emergencies points of considerations and key principles. https://www.who.int/docs/default-source/blue-print/working-group-for-vaccine-evaluation-(4th-consultation)/ap1-guidelines-online-consultation.pdf.

SUPPORTING INFORMATION FOR "SYMMETRIC VACCINE EFFICACY"

A PREPRINT

by Lucy D'Agostino McGowan, Sarah C. Lotspeich, and Michael G. Hudgens

December 9, 2025

Web Appendix A Delta Method and Variance Estimation

This appendix provides details regarding the delta method derivation of the asymptotic variance of \widehat{SVE} . In the main text, the multivariate delta method is used to show that \widehat{SVE} is asymptotically normal. The delta method requires the gradient ∇g of $g(p_0,p_1)=(p_0-p_1)/\max(p_0,p_1)$ exists and is continuous throughout the interior of the parameter space. To show this, note $g(p_0,p_1)$ is defined piecewise according to whether $p_0>p_1$ or $p_0< p_1$. To establish differentiability, consider the partial derivatives within each region. When $p_0>p_1$

$$\frac{\partial g}{\partial p_0} = \frac{p_1}{p_0^2}, \quad \frac{\partial g}{\partial p_1} = -\frac{1}{p_0},$$

whereas for $p_0 < p_1$

$$\frac{\partial g}{\partial p_0} = \frac{1}{p_1}, \quad \frac{\partial g}{\partial p_1} = -\frac{p_0}{p_1^2}.$$

Next note the partial derivatives also exist at points (p, p) along the boundary between the regions; in particular,

$$\partial g/\partial p_0 = \lim_{h \to 0^+} \frac{g(p+h,p) - g(p,p)}{h} = \lim_{h \to 0^-} \frac{g(p+h,p) - g(p,p)}{h} = \frac{1}{n}$$

and

$$\partial g/\partial p_1 = \lim_{h \to 0^+} \frac{g(p, p+h) - g(p, p)}{h} = \lim_{h \to 0^-} \frac{g(p, p+h) - g(p, p)}{h} = -\frac{1}{p}.$$

Finally, note the partial derivatives are continuous, including at points (p, p), i.e.,

$$\lim_{(p_0,p_1)\to(p,p)}\frac{\partial g}{\partial p_0}=\frac{1}{p},\quad \lim_{(p_0,p_1)\to(p,p)}\frac{\partial g}{\partial p_1}=-\frac{1}{p}.$$

Thus, the gradient of $g(p_0, p_1)$ exists and is continuous throughout the interior of the parameter space, including along the diagonal where $p_0 = p_1$. It then follows from the delta method that in large samples

$$\operatorname{Var}(\widehat{\text{SVE}}) \approx \frac{1}{n} \nabla g^{\top} \Sigma \nabla g = \begin{cases} \frac{p_1^2 \sigma_0^2 + p_0^2 \sigma_1^2}{p_0^4} & \text{if } p_0 > p_1\\ \frac{p_1^2 \sigma_0^2 + p_0^2 \sigma_1^2}{p_1^4} & \text{if } p_1 \ge p_0 \end{cases}$$
(S.1)

where $\sigma_j^2 = p_j (1 - p_j)/n_j$ for j = 0, 1. This variance can be consistently estimated by the plug-in estimator $\widehat{\text{Var}}(\widehat{\text{SVE}})$, defined by replacing p_j and σ_j in (S.1) with \hat{p}_j and $\hat{\sigma}_j^2$ for j = 0, 1.

Web Appendix B

Web Appendix B.1 Estimator Finite-sample Bias

The estimator $\widehat{\text{SVE}}$ is consistent for SVE, but exhibits finite-sample bias, a known issue for ratio estimators (Jewell, 1986). When $p_0 \neq p_1$, a second-order Taylor expansion gives the following approximations to the bias. When $p_0 > p_1$,

$$\operatorname{Bias}(\widehat{\text{SVE}}) = \mathbb{E}(\widehat{\text{SVE}}) - \operatorname{SVE} \approx -p_1(1-p_0)/(n_0p_0^2).$$

Note

$$\left| -\frac{p_1(1-p_0)}{n_0 p_0^2} \right| \le \frac{p_1(1-p_0)}{n_0 p_0^2} \le \frac{1-p_0}{n_0 p_0} \le \frac{1}{n_0 p_0}$$

Thus the bias will tend to be small except in smaller trials where n_0p_0 , the expected number of events in the control arm, is small. Likewise, when $p_1 > p_0$,

$$\operatorname{Bias}(\widehat{\text{SVE}}) = \mathbb{E}(\widehat{\text{SVE}}) - \operatorname{SVE} \approx p_0(1 - p_1)/(n_1 p_1^2),$$

which is bounded above by $1/(n_1p_1)$. The results above suggest the finite-sample bias of $\widehat{\text{SVE}}$ might be partially mitigated by using the bias-corrected SVE estimator

$$\widehat{SVE}_{BC} = \begin{cases} \widehat{SVE} + \frac{\hat{p}_1(1 - \hat{p}_0)}{n_0 \hat{p}_0^2} & \text{if } \hat{p}_0 > \hat{p}_1, \\ \widehat{SVE} - \frac{\hat{p}_0(1 - \hat{p}_1)}{n_1 \hat{p}_1^2} & \text{if } \hat{p}_1 > \hat{p}_0, \\ \widehat{SVE} & \text{if } \hat{p}_0 = \hat{p}_1. \end{cases}$$
(S.2)

The bias corrected estimator subtracts an estimator of the bias from the original SVE estimator, using plug-in estimates \hat{p}_0 and \hat{p}_1 in place of p_0 and p_1 . The correction is asymptotically negligible (vanishing at rate $O(n^{-1})$) but may reduce bias in finite samples.

Web Figure 1 shows the bias \widehat{SVE} and \widehat{SVE}_{BC} across the simulation scenarios. The empirical bias of \widehat{SVE} shown in Web Figure 1a is small or negligible across all scenarios. The finite-sample bias is greatest when p_0 and p_1 are small and the corresponding sample size is small. Web Figure 1b shows the bias of \widehat{SVE}_{BC} , demonstrating that the bias correction effectively reduces the finite-sample bias in scenarios with small sample sizes and low event probabilities.

Web Appendix B.2 Standard Error Ratio

Web Figure 2 shows the ratio of averaged estimated standard error $\widehat{\text{Var}}(\widehat{\text{SVE}})^{1/2}$ to the empirical standard error (SE) of $\widehat{\text{SVE}}$ from the simulation study. The ratios are close to 1 across all scenarios, indicating accurate variance estimation.

Web Appendix B.3 Comparison of SVE and VE Confidence Interval Widths

Web Figure 3 shows the ratio of 95% CI widths for traditional VE versus SVE for simulations where $n_0 = n_1 = 1000$. When the vaccine is protective (i.e., $p_1 < p_0$), estimates of SVE and VE tend to be similar with CIs of similar average width. However, when the vaccine is harmful (i.e., $p_1 > p_0$), confidence intervals for traditional VE become extremely wide, while those for SVE remain stable. Confidence intervals for traditional VE were more than 80 times as wide as those for SVE in the extreme case when p_1 was much higher than p_0 .

Web Appendix B.4 Type I Error

Web Figure 4 presents empirical type I error rates under the null (SVE = 0). Type I error control was strongest for the profile likelihood intervals, followed by the tanh-Wald intervals, and poorest for the original-scale Wald intervals.

Web Appendix C Application to an HIV Vaccine Trial

Overall and subgroup-level empirical HIV-1 infection risks are shown in Web Table 1, as well as VE and SVE estimates with corresponding 95% confidence intervals (CIs). The CIs for SVE were obtained using the profile likelihood method.

References

Jewell, N. P. (1986). On the bias of commonly used measures of association for 2 x 2 tables. *Biometrics* 42, 351–358.

Table 1: Estimated risk of HIV-1 infection (number of infections/number of participants) in the vaccine and placebo groups, with estimates and 95% confidence intervals (CIs) of traditional vaccine efficacy (VE) and symmetric vaccine efficacy (SVE)

Category	Vaccine	Placebo	VE (95% CI)	SVE (95% CI)
All volunteers	241/3598 (0.07)	127/1805 (0.07)	0.05 (-0.17 to 0.23)	0.05 (-0.15 to 0.22)
Men	239/3391 (0.07)	123/1704 (0.07)	0.02 (-0.20 to 0.21)	0.02 (-0.17 to 0.21)
Women	2/207 (0.01)	4/101 (0.04)	0.76 (-0.31 to 0.95)	0.76 (-0.19 to 0.97)
Race				
White (non-Hispanic)	211/2994 (0.07)	98/1495 (0.07)	-0.08 (-0.36 to 0.15)	-0.07 (-0.26 to 0.14)
Men	211/2930 (0.07)	98/1468 (0.07)	-0.08 (-0.36 to 0.14)	-0.07 (-0.27 to 0.14)
Hispanic	14/239 (0.06)	9/128 (0.07)	0.17 (-0.87 to 0.63)	0.17 (-0.49 to 0.62)
Men	13/211 (0.06)	9/114 (0.08)	0.22 (-0.77 to 0.66)	0.22 (-0.46 to 0.65)
Black (non-Hispanic)	6/233 (0.03)	9/116 (0.08)	0.67 (0.09 to 0.88)	0.67 (0.10 to 0.89)
Men	5/121 (0.04)	5/59 (0.08)	0.51 (-0.62 to 0.85)	0.51 (-0.41 to 0.86)
Women	1/112 (0.01)	4/57 (0.07)	0.87 (-0.11 to 0.99)	0.87 (0.16 to 0.99)
Asian (all men)	3/56 (0.05)	3/21 (0.14)	0.62 (-0.71 to 0.92)	0.62 (-0.47 to 0.93)
Other	7/76 (0.09)	8/45 (0.18)	0.48 (-0.33 to 0.80)	0.48 (-0.26 to 0.81)
Men	7/73 (0.10)	8/42 (0.19)	0.50 (-0.29 to 0.80)	0.50 (-0.23 to 0.81)
Nonwhite	30/604 (0.05)	29/310 (0.09)	0.47 (0.13 to 0.68)	0.47 (0.13 to 0.68)
Men	28/461 (0.06)	25/236 (0.11)	0.43 (0.04 to 0.66)	0.43 (0.03 to 0.66)
Women	2/143 (0.01)	4/74 (0.05)	0.74 (-0.38 to 0.95)	0.74 (-0.23 to 0.96)
Age				
≤ 30 years	84/971 (0.09)	43/504 (0.09)	-0.01 (-0.44 to 0.29)	-0.01 (-0.31 to 0.28)
> 30 years	157/2627 (0.06)	84/1301 (0.06)	0.07 (-0.20 to 0.28)	0.07 (-0.17 to 0.28)
Education level				
Less than college degree	95/1409 (0.07)	52/713 (0.07)	0.08 (-0.28 to 0.33)	0.08 (-0.22 to 0.33)
College or graduate degree	146/2188 (0.07)	75/1092 (0.07)	0.03 (-0.27 to 0.26)	0.03 (-0.22 to 0.25)
Baseline behavioral risk score				
Low risk	32/1211 (0.03)	11/609 (0.02)	-0.46 (-1.88 to 0.26)	-0.32 (-0.67 to 0.23)
Medium risk	177/2229 (0.08)	90/1107 (0.08)	0.02 (-0.25 to 0.23)	0.02 (-0.20 to 0.23)
High risk	32/158 (0.20)	26/89 (0.29)	0.31 (-0.08 to 0.56)	0.31 (-0.09 to 0.56)




Figure 1: Bias heatmap for the SVE estimator (a) without the bias correction and (b) with the bias correction. Each cell represents the average bias ($\widehat{SVE} - SVE$ or $\widehat{SVE}_{BC} - SVE$) over 10,000 simulations for a given combination of risk if unvaccinated (p_0) , risk if vaccinated (p_1) and sample sizes $(n_0 \text{ and } n_1)$. Both estimators exhibit relatively minimal bias across all scenarios, with the bias-corrected SVE estimator \widehat{SVE}_{BC} having slightly reduced bias compared to the uncorrected estimator \widehat{SVE} , particularly in scenarios with smaller sample sizes and lower risks.




Figure 2: Ratio of averaged estimated standard error $\widehat{\text{Var}}(\widehat{\text{SVE}})^{1/2}$ to the empirical standard error (SE) of $\widehat{\text{SVE}}$ from the simulation study. Values near 1 (white) indicate accurate variance estimation. Orange indicates overestimation of the standard error, while blue indicates underestimation.




Figure 3: The ratio of 95% confidence interval widths for traditional vaccine efficacy (VE) to symmetric vaccine efficacy (SVE). The bottom horizontal axis shows values of SVE, and the corresponding values of traditional VE are shown on the top horizontal axis. The shaded region indicates where VE = SVE, corresponding to positive efficacy. When efficacy is negative (unshaded region), the traditional VE confidence intervals can become extremely wide relative to SVE confidence intervals. The vertical dashed line represents where VE and SVE are both equal to 0.




Figure 4: Type I error rates under the null hypothesis (vaccine has no effect) across varying shared infection risks $(p_0 = p_1)$ and sample sizes (n_0, n_1) . Three types of confidence intervals were considered: a profile likelihood interval (Profile), a Wald interval on the original SVE scale (Wald), and a back-transformed tanh-Wald interval (tanh-Wald). Each panel displays the empirical type I error as a function of the infection risk, with columns corresponding to the vaccinated group sample size n_1 and rows to the unvaccinated group sample size n_0 . The dashed horizontal line marks the nominal level of 0.05. When sample sizes are large and balanced (e.g., $n_0 = n_1 = 1,000$), type I error is relatively well controlled across all infection risks. However, type I error is more variable in smaller sample sizes, particularly at small infection risks (e.g., $p_0 = p_1 = 0.1$), where noticeable inflation is observed for both Wald-type methods. The profile likelihood interval maintains nominal type I error across all scenarios.